z-logo
Premium
Synthesis and structural identification of fluorine‐18 labeled parathyroid hormone
Author(s) -
Yang Yang,
Richter Susan,
Wuest Frank,
Doschak Michael R.
Publication year - 2015
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.3328
Subject(s) - chemistry , parathyroid hormone , in vivo , pharmacokinetics , specific activity , ex vivo , radiochemistry , medicine , in vitro , biochemistry , calcium , enzyme , microbiology and biotechnology , organic chemistry , biology
Parathyroid hormone (PTH) is an 84 amino acid peptide hormone that plays a key role in bone and mineral metabolism. The biological actions of PTH are mediated via the N ‐terminal PTH(1–34) fragment, serving as the PTH receptor‐binding sequence, and which is therefore used clinically to treat conditions of low bone mass such as osteoporosis. In this study, PTH(1–34) was conjugated with non‐radioactive (stable F isotope) N ‐succinimidyl 4‐fluorobenzoate (SFB) leading to three isomeric mono ‐fluorobenzoated (FBz) PTH followed by Liquid chromatography‐Tandem mass spectrometry (LC‐MS/MS) assisted structural identification. Corresponding [ 18 F]SFB‐labeled PTH derivatives were prepared respectively and the Lys 13 site‐specific labeled [ 18 F]FBz PTH was isolated by HPLC with radiochemical purity >99% and specific activity of 2.78 GBq/µmol, suitable for future application with in vivo pharmacokinetic/pharmacodynamic studies of PTH, using preclinical Positron Emission Tomography Computed Tomography (PET/CT) imaging.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here